Scientists at Oregon Health & Science University, University Cancer Institute target prostate cancer therapy
2007 NOV 19 -- A report, 'Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel,' is newly published data in Investigational New Drugs. According to recent research published in the journal Investigational New Drugs, "Based on the pre-clinical spectrum of activity in taxane-resistant cell lines, we evaluated KOS-862 (epothilone D; 12,13-desoxyepothilone B) as second-line chemotherapy in androgen-independent prostate cancer.Thirty-eight men with metastatic androgen-independent prostate cancer and evidence of progression following docetaxel-based chemotherapy were treated with KOS-862, 100 mg/m2 (maximum of 240 mg) i.v. weekly for 3 weeks, repeated every 4 weeks. The primary objective for this study was to determine the antitumor activity, measured by PSA decline by more then 50% confirmed 4 weeks later.Two patients (5.3%, 90% CI 1-16%) met criteria for confirmed PSA decline." "While both of these patients had previously been treated with docetaxel, neither had confirmed docetaxel-refractory disease. None of the 24 patients with measurable disease had a confirmed partial response. Seventy-three percent of patients had an adverse event leading to dose delay, reduction, or treatment discontinuation. Neurological toxicity and fatigue predominated. Seventeen patients (44.7%) had treatment related grade 3 neurological adverse events including peripheral sensory neuropathy (n=4, 10.5%), ataxia (n=3, 7.9%), peripheral motor neuropathy (n=1, 2.6%), involuntary muscle contractions (n=1, 2.6%) and neuropathic pain (n=1, 2.6%)," wrote T.M. Beer and colleagues, Oregon Health & Science University, University Cancer Institute. The researchers concluded: "One subject (2.6%) had a grade 4 treatment peripheral motor neuropathy.Further study of this dose and schedule of KOS-862 in this patient population cannot be recommended due to both lack of activity and excessive toxicity." Beer and colleagues published their study in Investigational New Drugs (Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Investigational New Drugs, 2007;25(6):565-70). For additional information, contact T.M. Beer, Oregon Health & Science University Cancer Institute, Dept. of Medicine, Portland OR 97239 USA.. The publisher's contact information for the journal Investigational New Drugs is: Kluwer Academic Publ, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands. Keywords: United States, Prostate Cancer Therapy, Chemotherapy, Clinical Trial Research, Docetaxel, Drug Resistance, Drug Therapy, Drugs, Oncology, Pharmaceuticals, Prostate Cancer, Prostatic Neoplasms, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
